Rhythm Pharmaceuticals Inc Cash Flow Conversion Efficiency
Rhythm Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Rhythm Pharmaceuticals Inc (RYTM) has a cash flow conversion efficiency ratio of -0.183x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.39 Million) by net assets ($139.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Rhythm Pharmaceuticals Inc (2012–2025)
Cash flow conversion efficiency of Rhythm Pharmaceuticals Inc from 2012 to 2025. This chart illustrates how Rhythm Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RYTM share price today for real-time trading data and today's change.
Rhythm Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Rhythm Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Rhythm Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rhythm Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see market cap of Rhythm Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marfrig Global Foods S.A.
SA:MRFG3
|
0.234x |
|
QMMM Holdings Limited Ordinary Shares
NASDAQ:QMMM
|
-0.103x |
|
The Mosaic Company
NYSE:MOS
|
0.014x |
|
Unigroup Guoxin Microelectronics Co Ltd
SHE:002049
|
-0.011x |
|
MGIC Investment Corp
NYSE:MTG
|
0.037x |
|
Walsin Technology Corp
TW:2492
|
0.013x |
|
Bruker Corporation
NASDAQ:BRKR
|
0.092x |
|
UL Solutions Inc.
NYSE:ULS
|
0.164x |
Annual Cash Flow Conversion Efficiency for Rhythm Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Rhythm Pharmaceuticals Inc from 2012 to 2025. Review Rhythm Pharmaceuticals Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $139.07 Million | $-115.67 Million | -0.832x | -20.19% |
| 2024-12-31 | $164.55 Million | $-113.88 Million | -0.692x | +13.71% |
| 2023-12-31 | $169.76 Million | $-136.16 Million | -0.802x | -22.21% |
| 2022-12-31 | $264.26 Million | $-173.43 Million | -0.656x | -27.72% |
| 2021-12-31 | $284.15 Million | $-146.00 Million | -0.514x | +29.85% |
| 2020-12-31 | $166.53 Million | $-121.98 Million | -0.732x | -67.69% |
| 2019-12-31 | $281.02 Million | $-122.75 Million | -0.437x | -73.34% |
| 2018-12-31 | $246.26 Million | $-62.06 Million | -0.252x | -23.85% |
| 2017-12-31 | $144.79 Million | $-29.46 Million | -0.203x | +93.61% |
| 2016-12-31 | $7.30 Million | $-23.22 Million | -3.182x | -1359.47% |
| 2015-12-31 | $32.00 Million | $-6.98 Million | -0.218x | -101.04% |
| 2014-12-31 | $-358.00K | $-7.51 Million | 20.972x | +6190.74% |
| 2013-12-31 | $-57.46 Million | $-19.16 Million | 0.333x | -32.16% |
| 2012-12-31 | $-36.28 Million | $-17.83 Million | 0.491x | -- |
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, … Read more